The agency greenlit Jideytro for patients who have been previously treated with a ROS1 kinase inhibitor for ROS1-positive non-small cell lung cancer.
July 22, 2026 02:21 PM EDT
FDA approves Nuvalent's cancer drug, a week after GSK closed $10.6B buyout
GSK’s $10.6 billion acquisition of Nuvalent is delivering surprisingly early results.
The FDA on Wednesday approved one of Nuvalent’s lung cancer medicines …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
GSK secures first lung cancer approval as FDA clears Jideytro in quick payoff from Nuvalent deal
FDA Greenlights GSK’s First Lung Cancer Drug Ahead of Schedule - GSK (NYSE:GSK)
Jideytro nabs FDA approval as second-line treatment in non-small cell lung cancer
GSK lung cancer drug gets speedy approval following $10.6B deal
